National Institutes of Health to Grant Exclusive License to S'LIL Pharmaceuticals for Therapeutic Polyamines

Summary

The National Institutes of Health is considering granting an exclusive worldwide license to S'LIL Pharmaceuticals to practice therapeutic polyamines, as outlined in U.S. Patent No. 5,541,230 and a related patent application.